The first-in-class anti-CD47 antibody HU5F9-G4 with rituximab induces durable responses in relapsed/refractory DLBCL and indolent lymphoma: INTERIM phase 1B/2 results

Breaking down diagnostic and treatment algorithms to aid in the selection of front-line de novo acute myeloid leukaemia therapy

Rituximab maintenance for patients with diffuse large B-cell lymphoma in first complete remission: results from a randomized HOVON-NORDIC Lymphoma group phase III study

CPI-0610, a bromodomain and extraterminal domain inhibitor, reduces pro-inflammatory cytokines, bone marrow fibrosis and the number of transfusions in myelofibrosis patients

Targeting aberrant DNA methylation as a novel and uniform therapeutic strategy for the treatment of T-cell acute lymphoblastic leukemia and lymphoma

ASCEND Phase 3 study of acalabrutinib vs investigator's choice of rituximab plus idelalisib or bendamustine in patients with relapsed/refractory chronic lymphocytic leukemia

A randomized controlled phase III clinical trial comparing recombinant interferon alpha-2 vs. hydroxyurea in patients with myeloproliferative neoplasms -Three-year analysis of the DALIAH trial

Sotatercept (ACE-011) in subjects with MPN-associated myelofibrosis and anemia

Is iron chelation really necessary in MDS?

Complex evaluation of cellular and humoral immunity in patients with chronic lymphocytic leukemia

NGS technologies in AML: Time to use in clinical care?

Large B-cell lymphomas

Tipifernib in relapsed or refractory angioimmunoblastic T-cell lymphoma and CXCL12+ peripheral T-cell lymphoma

Results from the randomized placebo- controlled phese 3 HOPE trial of voxelotor in adults and adolescents with sickle cell disease

Immunotherapy in relapsed/refractory multiple myeloma

New therapies in AML